Nyrada Inc. (ASX:NYR) Progresses Phase I Clinical Trial
Clinical Trial Update
Nyrada Inc. (ASX:NYR) announced that its Phase I clinical trial Safety Review Committee has reviewed safety and pharmacokinetic data from the first dosed cohort. With no issues raised, the trial will proceed to the second cohort, and recruitment is already underway. Final readouts are expected in the third quarter of CY2025. Regular updates will be provided throughout the trial.
Lead Drug Candidate NYR-BI03
Nyrada is developing NYR-BI03, a small molecule first-in-class drug for neuroprotection and cardioprotection indications. Previous preclinical studies have demonstrated significant neuroprotective and cardioprotective effects, positioning NYR-BI03 for first-in-human trials.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.